Abstract 1864P
Background
Globally, more than 1.3 mio adolescents and young adults (AYAs) are diagnosed with cancer each year. Long-term survival has increased due to improved cancer therapy; however, a potential side effect is reduced fertility. Despite development in fertility preservation uncertainty regarding future fertility is still of major concern to the AYAs. The aim of this study was to identify to what extent nulliparous, female AYAs with cancer have children after cancer treatment compared to nulliparous female AYAs without cancer.
Methods
This is a national register study based on the Danish National Assisted Reproductive Technology-Couple cohort including female AYAs diagnosed with cancer when aged 18-39 from 1978–2016. According to diagnosis onset, the female AYAs with cancer were randomly age-matched with 60 female AYAs without cancer (comparison group: CG). Study participants were followed until end of study, death, or migration (31/12-2017). Death was incorporated as a competing risk in all analyses. Hazard Ratio (HR) were calculated, comparing the female AYAs with cancer with the CG. HR was adjusted for time of diagnosis, immigration status, marital status, and educational level.
Results
33.3% of AYAs with cancer had at least one child after cancer treatment vs. 40% in the CG. Female AYAs with malignant melanoma had solely a higher HR of having children after cancer treatment compared to the CG. Female AYAs with leukaemia, breast and CNS cancer had the lowest HR of having children after cancer treatment, especially in the age interval 32-39 years. Table: 1864P
N (%) | ≥ 1 child after cancer N (%) | Adjusted HR (95% CI)* | |||
18-25 y | 26-31 y | 32-39 y | |||
All | 7519 (100) | 2505 (33.3) | 0.77 (0.72-0.82) | 0.65 (0.61-0.69) | 0.59 (0.52-0.67) |
Gyn cancer | 1773 (23.6) | 435 (24.5) | 0.49 (0.42-0.58) | 0.44 (0.38-0.50) | 0.39 (0.29-0.52) |
Breast cancer | 1115 (14.8) | 179 (16.1) | 0.63 (0.42-0.95) | 0.46 (0.37-0.56) | 0.35 (0.26-0.48) |
Mal melanoma | 1960 (26.1) | 1071 (54.6) | 1.02 (0.93-1.12) | 1.03 (0.93-1.13) | 1.13 (0.92-1.39) |
CNS cancer | 303 (4.0) | 65 (21.5) | 0.70 (0.51-0.97) | 0.40 (0.26-0.61) | 0.25 (0.06-0.97) |
Leukaemia | 258 (3.4) | 37 (14.3) | 0.39 (0.26-0.57) | 0.25 (0.09-0.65) | 0.41 (0.13-1.26) |
Lymphoma | 278 (3.7) | 78 (28.1) | 0.63 (0.47-0.85) | 0.48 (0.30-0.75) | 0.76 (0.32-1.84) |
CG | 499,616 | 199,861 (40.0) | 1 | 1 | 1 |
*Adjusted analysis is based on complete case sample, N=6275. Approximately 16% (6275/7519) is excluded in the adjusted analysis due to missing data.
Conclusions
A third of nulliparous, female AYAs with cancer had at least one child after cancer which is lower than for female AYAs without cancer. The HR for having children after cancer decrease with increased age being lowest in female AYAs with leukaemia, breast- and CNS cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1878P - Prevalence of burnout in GU oncologists in central Asia: BUCARE survey
Presenter: Oxana Shatkovskaya
Session: Poster session 05
1879P - Investigating the effect of family support on the mental health of patients with breast cancer
Presenter: Maryam Garousi
Session: Poster session 05
1880P - Cancer care: Psychoeducational intervention for first-year residents of a general hospital in northeastern Mexico
Presenter: Celia Beatriz Gonzalez-Alcorta
Session: Poster session 05
1991P - Safety and effectiveness of surgery or radiotherapy after PD-L1 Inhibitor (TQB-2450) and chemotherapy induction therapy in patients with limited-stage small cell lung cancer: A phase II trial
Presenter: Fenghuan Sun
Session: Poster session 05
1992P - A phase II safety and efficacy study of PM8002 (anti-PD-L1 x VEGF-A bispecific) combined with paclitaxel as a second-line therapy for small cell lung cancer (SCLC)
Presenter: Ying Cheng
Session: Poster session 05
1993P - Phase IIIb study of durvalumab plus platinum–etoposide in first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): Safety results
Presenter: Maria Dolores Isla Casado
Session: Poster session 05
1994P - Carboplatin, etoposide, bevacizumab, and atezolizumab in patients with extensive-stage SCLC – GOIRC-01-2019 CeLEBrATE ML41241 trial
Presenter: Karim Rihawi
Session: Poster session 05
1995P - Long-term benefit of atezolizumab plus chemotherapy in extensive stage small cell lung cancer (ES-SCLC): Exploratory analysis from the IMfirst study
Presenter: Maria Rosario Garcia Campelo
Session: Poster session 05
1996P - The impact of an etoposide shortage on patients with extensive-stage small cell lung cancer (ES-SCLC): Results of a natural experiment
Presenter: Claire Browne
Session: Poster session 05
1997P - A study of sintilimab combined with anlotinib and chemotherapy as second-line or later therapy in extensive-disease small cell lung cancer
Presenter: Zhe-Hai Wang
Session: Poster session 05